Targets for immunotherapy of liver cancer
Keywords: 
Cancer
HCC
Immunotherapy
Issue Date: 
2018
Publisher: 
Elsevier BV
Project: 
info:eu-repo/grantAgreement/MINECO/Proyectos de investigación en salud (Modalidad Proyectos de investigación en salud) (AE Salud 2016)/ PI16%2F01845/ES/Desarrollo terapéutico basado en la identificación, análisis e inhibición de genes no codificantes implicados en la progresión del hepatocarcinoma
602893 - HEPAVAC - Cancer Vaccine development for Hepatocellular Carcinoma
hepam
ISSN: 
0168-8278
Citation: 
Greten, T.F. (Tim F.); Sangro, B. (Bruno). "Targets for immunotherapy of liver cancer". Journal of hepatology (online). 68 (1), 2018, 157 - 166
Abstract
Drug development in hepatocellular carcinoma (HCC) has been characterised by many failures in the past. Despite good rationales and promising phase II data, many phase III trials failed. Immunotherapy represents an alternative treatment approach that has been successful in many different cancer types. As an inflammation induced cancer, HCC represents a very interesting target for immune based approaches. Indeed, early results from clinical trials testing immune checkpoint inhibitors are not only promising, but have already led to evaluation in a phase III setting. Herein, we summarise our current knowledge on the rationale, mechanism of action and clinical data for immune checkpoint blockade in HCC. In addition, we provide an overview of other novel immune based approaches currently under development for the treatment of HCC, such as adoptive cell based and antibody-based approaches.

Files in This Item:
Thumbnail
File
1-s2.0-S0168827817322870-main.pdf
Description
Size
2.77 MB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.